Key Players
Competitive Landscape
Hypoimmune cell therapy market includes replacement-cell developers, allogeneic immune-cell companies and iPSC platform specialists. Sana Biotechnology and Century Therapeutics are focusing on protected islet cells, whereas Fate Therapeutics and CRISPR Therapeutics are developing edited immune-cell platforms. Allogene Therapeutics and Caribou Biosciences are developing allogeneic CAR-T products, while Vertex Pharmaceuticals, Cellectis, Nkarta and Sernova are participating through replacement cells, genome engineering, NK cells or cell delivery. Increasing focus on clinical evidence, master cell bank control and manufacturing consistency is expected to increase competition in the hypoimmune cell therapy market.
During 2026, companies increased focus on manufacturing readiness, clinical delivery and continuation of priority cell therapy programs. Century Therapeutics reported five consistent clinical-scale CNTY-813 runs in October 2026.[6] In April 2026, Sana Biotechnology and Mayo Clinic announced a collaboration for SC451 handling, delivery and follow-up.[5] CRISPR Therapeutics reported in August 2026 that CASGEVY was approved in 39 countries, whereas Caribou announced in October 2026 that it planned to discontinue CB-011 and vispa-cel.[15] These developments shows that manufacturing consistency and availability of treatment networks will remain important factors for company participation during the forecast period.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| October 2026: Caribou planned to discontinue CB-011 and vispa-cel while reviewing strategic alternatives. | Financing must support later-stage cell-therapy trials. | Portfolio continuity is becoming a visible qualification factor. | Assets may move through a merger, acquisition, or licensing transaction. |
| October 2026: Century reported five consistent clinical-scale CNTY-813 manufacturing runs. | Replacement cells require repeatable batch quality. | iPSC programs are advancing manufacturing before first patient dosing. | Consistent runs can support IND review and early clinical supply. |
| August 2026: CRISPR Therapeutics reported CASGEVY approval in 39 countries. | Authorized cell therapies require cross-market treatment networks. | Commercial infrastructure is expanding beyond a single jurisdiction. | Established collection and treatment routes can inform later edited-cell launches. |
| April 2026: Sana and Mayo Clinic formed an SC451 clinical and operational collaboration. | Islet therapy requires standardized handling and follow-up. | Developers are designing center workflows before pivotal evidence. | Validated protocols can support consistent delivery at additional sites. |
Source: Future Market Insights, Hypoimmune Cell Therapy Market Report, 2026-2036.
Sana Biotechnology and Century Therapeutics are focusing on immune-protected replacement cells, but the companies differs by donor source, manufacturing stage and human exposure. Fate Therapeutics, CRISPR Therapeutics and Allogene Therapeutics are more focused on engineered immune-cell platforms. Caribou Biosciences remains part of the clinical evidence base, although its announced program discontinuation is expected to limit its present participation.
Who leads the hypoimmune cell therapy market?
Public evidence does not establish one verified market-share leader in hypoimmune cell therapy market. Sana Biotechnology has direct human follow-up for hypoimmune islets, whereas Century Therapeutics has renewable manufacturing evidence. CRISPR Therapeutics has wider edited-cell clinical and treatment infrastructure. Company position is therefore expected to depend on durable cell function, clinical progress and repeatable manufacturing rather than one platform claim.
Which companies have documented product-level evidence?
Sana Biotechnology has human follow-up data for UP421, CRISPR Therapeutics has clinical zugo-cel data and Century Therapeutics has current CNTY-813 manufacturing evidence. Allogene Therapeutics and Caribou Biosciences also have allogeneic CAR-T evidence, although current program status is different across these companies. Increasing product-level evidence is expected to influence company participation over the forecast period.
What should buyers evaluate before approving a supplier?
Cell therapy centers requires product identity, genomic integrity, potency, conditioning, release tests, comparability and cold-chain controls before using an edited-cell therapy. Control of master cell bank and availability of technical support after manufacturing change are also expected to influence supplier selection. Products having repeatable release results and clear administration procedure are likely to receive higher preference among specialist centers.
How is competition expected to change through 2036?
Competition is expected to increase among programs providing durable cell function, repeatable manufacturing and manageable clinical delivery. Portfolio withdrawals and financing limitations may restrict the continuation of some programs. However, new trial clearances, renewable cell banks and expansion of qualified treatment centers are expected to create growth opportunities through 2036.
Representative Company Overview
| Company | Positioning | Verified development |
|---|---|---|
| Sana | Protected islet development | March 2026: UP421 function reported through 14 months without immunosuppression. |
| Fate | iPSC immune-cell platform | August 2026: FT839 IND clearance reported for autoimmune disease. |
| Century | iPSC replacement cells | October 2026: five clinical-scale CNTY-813 runs and 11-month mouse data reported. |
| CRISPR Therapeutics | Edited immune and replacement cells | August 2026: CASGEVY approval reported in 39 countries. |
| Allogene | Allogeneic CAR-T | August 2026: RESOLUTION program update reported. |
| Caribou | Immune-cloaked CAR-T | October 2026: CB-011 and vispa-cel discontinuation plan announced. |
| Vertex | Islet replacement | May 2025: VX-264 discontinued after missing its efficacy endpoint. |
| Cellectis | Genome engineering | September 2026: internal strategy shifted toward in vivo gene editing. |
| Nkarta | NK-cell development | April 2026: outpatient NKX019 protocol agreement reported. |
| Sernova | Cell-delivery platform | September 2026: definitive Seraxis merger agreement announced. |
Research Methodology
The companies included in the report represents current market structure and does not indicate a market-share ranking. Company inclusion is based on public evidence for immune-evasion engineering, allogeneic cell development, replacement-cell manufacturing, clinical activity or cell-delivery capability. Primary research includes manufacturers, developers, cell therapy centers, distributors and industry experts. Desk research covers regulatory records, official company announcements, filings and technical publications. Market estimates are checked with company activity, clinical progress, manufacturing readiness and country adoption conditions.
